A detailed history of Zions Bancorporation, N.A. transactions in Argenx Se stock. As of the latest transaction made, Zions Bancorporation, N.A. holds 14 shares of ARGX stock, worth $8,733. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14
Previous 11 27.27%
Holding current value
$8,733
Previous $4,000 75.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$434.22 - $551.9 $1,302 - $1,655
3 Added 27.27%
14 $7,000
Q2 2024

Aug 08, 2024

BUY
$356.01 - $451.55 $712 - $903
2 Added 22.22%
11 $4,000
Q1 2024

May 14, 2024

SELL
$356.95 - $413.29 $2,141 - $2,479
-6 Reduced 40.0%
9 $3,000
Q4 2023

Feb 12, 2024

BUY
$338.91 - $506.01 $1,694 - $2,530
5 Added 50.0%
15 $5,000
Q1 2023

May 10, 2023

SELL
$334.23 - $403.65 $2,673 - $3,229
-8 Reduced 44.44%
10 $3,000
Q4 2022

Feb 10, 2023

BUY
$342.17 - $402.31 $2,395 - $2,816
7 Added 63.64%
18 $6,000
Q3 2022

Nov 08, 2022

BUY
$343.2 - $395.75 $1,029 - $1,187
3 Added 37.5%
11 $4,000
Q1 2022

May 13, 2022

BUY
$254.45 - $351.06 $508 - $702
2 Added 33.33%
8 $3,000
Q4 2021

Feb 11, 2022

SELL
$272.01 - $353.03 $2,992 - $3,883
-11 Reduced 64.71%
6 $2,000
Q3 2021

Nov 10, 2021

BUY
$295.0 - $350.58 $1,475 - $1,752
5 Added 41.67%
17 $5,000
Q2 2021

Aug 11, 2021

BUY
$257.11 - $319.92 $1,285 - $1,599
5 Added 71.43%
12 $4,000
Q1 2021

May 13, 2021

BUY
$268.3 - $380.31 $268 - $380
1 Added 16.67%
7 $2,000
Q4 2020

Feb 12, 2021

BUY
$248.13 - $308.36 $744 - $925
3 Added 100.0%
6 $2,000
Q3 2020

Nov 13, 2020

BUY
$215.51 - $272.51 $646 - $817
3 New
3 $1,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.5B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Zions Bancorporation, N.A. Portfolio

Follow Zions Bancorporation, N.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zions Bancorporation, N.A., based on Form 13F filings with the SEC.

News

Stay updated on Zions Bancorporation, N.A. with notifications on news.